BioVie, Inc. Common Stock
$1.72
-$0.03 (-1.71%)
$1.69Day Range$1.82
Key Statistics
Market Cap
$14.93M
Shares Outstanding
8.5M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jan 14, 2014
Round Lot
100
Locale
US
Trading Data
Day Open
$1.76
Day High
$1.82
Day Low
$1.69
Volume
440.0K
VWAP
$1.76
Prev Close
$1.75
Transactions
--
Acc. Volume
--
About BioVie, Inc. Common Stock
BioVie Inc is a clinical-stage company developing drug therapies for the treatment of neurological and neurodegenerative disorders and liver disease. Its therapeutic areas include Alzheimer's, Parkinson's, Long COVID, Ascites, Longevity, and Epigenetics. In liver disease, its investigational drug candidate BIV201 (continuous infusion terlipressin) was granted FDA Fast Track status and FDA Orphan Drug designation for ascites due to all etiologies except cancer. BIV201 is being evaluated as a treatment option for patients suffering from life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.
PHARMACEUTICAL PREPARATIONSSIC 283413 employees680 W NYE LANE, CARSON CITY, NV, 89703775-888-3162IPO Jan 14, 2014US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001580149
- Composite FIGI
- BBG00548BTD6
- Share Class FIGI
- BBG00548BTF4
- Ticker Root
- BIVI
- SIC Code
- 2834
About BioVie, Inc. Common Stock (BIVI) Stock
BioVie, Inc. Common Stock (BIVI) closed the 2026-09-16 session at $1.72, down 1.71% versus the previous close (-0.03). The stock opened at $1.76 and traded between $1.69 and $1.82 during that session. Session trading volume was 440K shares. The volume-weighted average price (VWAP) is $1.76.
BioVie Inc is a clinical-stage company developing drug therapies for the treatment of neurological and neurodegenerative disorders and liver disease. Its therapeutic areas include Alzheimer's, Parkinson's, Long COVID, Ascites, Longevity, and Epigenetics. In liver disease, its investigational drug candidate BIV201 (continuous infusion terlipressin) was granted FDA Fast Track status and FDA Orphan Drug designation for ascites due to all etiologies except cancer. BIV201 is being evaluated as a treatment option for patients suffering from life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.
BioVie, Inc. Common Stock has a market capitalization of $14.9 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. BIVI is listed on the XNAS exchange. The company employs approximately 13 people. BioVie, Inc. Common Stock is headquartered in CARSON CITY, NV. The recorded listing date is 2014-01-14.
On this page you can find market BIVI stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.